ResMed Inc. (TICKER: RMD) Benchmark And Performance Data

there are 11 of samples in the benchmark for ResMed Inc. in year 2023 in 2023. The total inventory for ResMed Inc. was $743,910,000.00 in 2022. The total inventory for ResMed Inc. was $457,033,000.00 in 2021. The total inventory for ResMed Inc. was $416,915,000.00 in 2020. The total inventory for ResMed Inc. was $349,641,000.00 in 2019. The total inventory for ResMed Inc. was $268,701,000.00 in 2018. The total inventory for ResMed Inc. was $268,319,000.00 in 2017. The total inventory for ResMed Inc. was $246,859,000.00 in 2015. The total inventory for ResMed Inc. was $224,456,000.00 in 2016. The total inventory for ResMed Inc. was $165,418,000.00 in 2014. The total inventory for ResMed Inc. was $145,847,000.00 in 2013. The sales, general, and administrative (SGA) for ResMed Inc. was $737,508,000.00 in 2022. The sales, general, and administrative (SGA) for ResMed Inc. was $676,689,000.00 in 2020. The sales, general, and administrative (SGA) for ResMed Inc. was $670,387,000.00 in 2021. The sales, general, and administrative (SGA) for ResMed Inc. was $645,010,000.00 in 2019. The sales, general, and administrative (SGA) for ResMed Inc. was $600,369,000.00 in 2018. The sales, general, and administrative (SGA) for ResMed Inc. was $553,968,000.00 in 2017. The sales, general, and administrative (SGA) for ResMed Inc. was $488,057,000.00 in 2016. The sales, general, and administrative (SGA) for ResMed Inc. was $478,627,000.00 in 2015. The sales, general, and administrative (SGA) for ResMed Inc. was $450,414,000.00 in 2014. The sales, general, and administrative (SGA) for ResMed Inc. was $430,802,000.00 in 2013. The sales, general, and administrative (SGA) for ResMed Inc. was $$874,000,000 in 2023. The revenue volatility for ResMed Inc. was 16.74% in 2023. The market capitalization for ResMed Inc. was $38,402,188,868.00 in 2013. The market capitalization for ResMed Inc. was $38,085,346,041.00 in 2014. The market capitalization for ResMed Inc. was $35,470,981,968.00 in 2015. The market capitalization for ResMed Inc. was $32,174,976,326.00 in 2019. The market capitalization for ResMed Inc. was $32,133,560,256.00 in 2020. The market capitalization for ResMed Inc. was $31,972,006,685.00 in 2017. The market capitalization for ResMed Inc. was $30,692,079,443.00 in 2016. The market capitalization for ResMed Inc. was $30,487,642,074.00 in 2018. The market capitalization for ResMed Inc. was $25,302,750,358.00 in 2022. The market capitalization for ResMed Inc. was $21,749,473,884.00 in 2021. The market capitalization for ResMed Inc. was $$27,969,000,000 in 2023. The gross revenue for ResMed Inc. was $3,578,127,000.00 in 2022. The gross revenue for ResMed Inc. was $3,196,825,000.00 in 2021. The gross revenue for ResMed Inc. was $2,957,013,000.00 in 2020. The gross revenue for ResMed Inc. was $2,606,572,000.00 in 2019. The gross revenue for ResMed Inc. was $2,340,196,000.00 in 2018. The gross revenue for ResMed Inc. was $2,066,737,000.00 in 2017. The gross revenue for ResMed Inc. was $1,838,713,000.00 in 2016. The gross revenue for ResMed Inc. was $1,678,912,000.00 in 2015. The gross revenue for ResMed Inc. was $1,554,973,000.00 in 2014. The gross revenue for ResMed Inc. was $1,514,457,000.00 in 2013. The gross revenue for ResMed Inc. was $$4,223,000,000 in 2023. The gross margin for ResMed Inc. was $27.28% in 2023. The days sales outstanding for ResMed Inc. was 55 days in 2023. The days payable outstanding for ResMed Inc. was 30 days in 2023. The days of inventory for ResMed Inc. was $170 in 2023. The cost of goods sold (COGS) for ResMed Inc. was 44.22% in 2023. The cost of goods sold (COGS) for ResMed Inc. was $894,469,000.00 in 2017. The cost of goods sold (COGS) for ResMed Inc. was $772,216,000.00 in 2016. The cost of goods sold (COGS) for ResMed Inc. was $667,516,000.00 in 2015. The cost of goods sold (COGS) for ResMed Inc. was $573,800,000.00 in 2013. The cost of goods sold (COGS) for ResMed Inc. was $565,187,000.00 in 2014. The cost of goods sold (COGS) for ResMed Inc. was $1,553,816,000.00 in 2022. The cost of goods sold (COGS) for ResMed Inc. was $1,357,725,000.00 in 2021. The cost of goods sold (COGS) for ResMed Inc. was $1,239,227,000.00 in 2020. The cost of goods sold (COGS) for ResMed Inc. was $1,112,501,000.00 in 2019. The cost of goods sold (COGS) for ResMed Inc. was $1,005,298,000.00 in 2018. The cost of goods sold (COGS) for ResMed Inc. was $$1,867,000,000 in 2023. The cash to cash cycle time for ResMed Inc. was 195 in 2023. The annual percentage growth rate of ResMed Inc. was -0.18% in 2023. ResMed Inc. in its benchmark peer group, had rank 5 days for days sales outstanding in 2023. ResMed Inc. in its benchmark peer group, had rank 4 for gross revenue in 2023. ResMed Inc. in its benchmark peer group, had rank 4 for cost of goods sold as a percent of revenue in 2023. ResMed Inc. in its benchmark peer group, had rank 11 for cash to cash cycle time in 2023. ResMed Inc. in its benchmark peer group, had rank 10 for sales growth in 2023. ResMed Inc. in its benchmark peer group, had rank 10 days for days of inventory in 2023. ResMed Inc. headquarters region is West. ResMed Inc. has ticker symbol RMD. ResMed Inc. has the following profile: ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.. ResMed Inc. has primary indstury Medical Instruments & Supplies. ResMed Inc. had a $$10,890,000,000 gap between actual performance and next performance rank for gross revenue in competitive benchmarking in 2023. ResMed Inc. had AptarGroup, and Baxter International, and Dentsply Sirona, and West Pharmaceutical Services, and Intuitive Surgical, and Becton Dickinson, and Envista Holdings, and Hologic, and Cooper Cos., and Teleflex, and ResMed Inc. benchmark peer companies for its SIC code in 2023. ResMed Inc. had 9.84% gap between actual performance and next performance rank for cost of goods sold as a percent of revenue in competitive benchmarking in 2023. ResMed Inc. had 70 days gap between actual performance and next performance rank for cash to cash in competitive benchmarking in 2023. ResMed Inc. had 54 days gap between actual performance and next performance rank for days of inventory in competitive benchmarking in 2023. ResMed Inc. had 4.12% gap between actual performance and next performance rank for sales volatility in competitive benchmarking in 2023. ResMed Inc. had 2 days gap between actual performance and next performance rank for days sales outstanding in competitive benchmarking in 2023. ResMed Inc. had 10,140 number of employees in 2023. ResMed Inc. had 0.15% gap between actual performance and next performance rank for sales growth in competitive benchmarking in 2023. ResMed Inc. had 0.00% gap between actual performance and next performance rank for gross margin in competitive benchmarking in 2023. ResMed Inc. can reduce overall cost by $$598,000,000 by improving both COGS and SGA to next benchmark tier in 2023. ResMed Inc. can reduce inventory with practices including SKU Reduction in 2023. ResMed Inc. can reduce inventory with practices including Reduce Manufacturing Latency in 2023. ResMed Inc. can reduce inventory with practices including Forecast Accuracy in 2023. ResMed Inc. can reduce inventory with practices including Demand Shaping in 2023. ResMed Inc. can reduce days sales outstanding with practices including in 2023. ResMed Inc. can increase sales revenue by $$10,890,000,000 improving sales performance to next benchmark tier in 2023. ResMed Inc. can increase revenue growth by $$6,000,000 by improving growth performance to next benchmark tier in 2023. ResMed Inc. can increase overall revenue by $$10,896,000,000 by improving both growth and sales performance to next benchmark tier in 2023. ResMed Inc. can increase days payables outstanding with practices including Strategic Sourcing in 2023. ResMed Inc. can increase days payables outstanding by $197,000,000 days by increasing days payables outstanding to next benchmark tier in 2023. ResMed Inc. can improve total financial performance by $$12,339,000,000 by improving revenue, costs, and working capital in 2023. ResMed Inc. can decrease overall working capital by $$845,000,000 by improving inventory, payables and receivables to next benchmark tier in 2023. ResMed Inc. can decrease inventory days by $625,000,000 days by reducing inventory days to next benchmark tier in 2023. ResMed Inc. can decrease days sales outstanding by $23,000,000 days by reducing days sales outstanding to next benchmark tier in 2023. ResMed Inc. can accelerate revenue growth practices including Revenue-optimized Planning in 2023. ResMed Inc. can accelerate revenue growth practices including Pricing Optimization in 2023. ResMed Inc. can accelerate revenue growth practices including Accelerate Design Pipeline in 2023. 97 days was the measured superior or top ten performance level for cash to cash cycle time in ResMed Inc.'s peer group in 2023. 97 days was the measured advantage or top third performance level for days of inventory in ResMed Inc.'s peer group in 2023. 83 days was the measured superior or top ten performance level for days of inventory in ResMed Inc.'s peer group in 2023. 7.67% was the measured advantage or top third performance level for sales volatility in ResMed Inc.'s peer group in 2023. 6.98% was the measured superior or top ten performance level for sales volatility in ResMed Inc.'s peer group in 2023. 56 days was the measured parity or middle performance level for days sales outstanding in ResMed Inc.'s peer group in 2023. 53 days was the measured advantage or top third performance level for days sales outstanding in ResMed Inc.'s peer group in 2023. 52 days was the measured superior or top ten performance level for days sales outstanding in ResMed Inc.'s peer group in 2023. 45.77% was the measured parity or middle performance level for cost of goods sold as a percent of revenue in ResMed Inc.'s peer group in 2023. 44.22% was the measured advantage or top third performance level for cost of goods sold as a percent of revenue in ResMed Inc.'s peer group in 2023. 34.38% was the measured superior or top ten performance level for cost of goods sold as a percent of revenue in ResMed Inc.'s peer group in 2023. 26.35% was the measured superior or top ten performance level for gross margin in ResMed Inc.'s peer group in 2023. 125 days was the measured parity or middle performance level for cash to cash cycle time in ResMed Inc.'s peer group in 2023. 12.62% was the measured parity or middle performance level for sales volatility in ResMed Inc.'s peer group in 2023. 116 days was the measured parity or middle performance level for days of inventory in ResMed Inc.'s peer group in 2023. 101 days was the measured advantage or top third performance level for cash to cash cycle time in ResMed Inc.'s peer group in 2023. 0.07% was the measured superior or top ten performance level for sales growth in ResMed Inc.'s peer group in 2023. -0.03% was the measured parity or middle performance level for sales growth in ResMed Inc.'s peer group in 2023. -0.02% was the measured advantage or top third performance level for sales growth in ResMed Inc.'s peer group in 2023. $18.89% was the measured advantage or top third performance level for gross margin in ResMed Inc.'s peer group in 2023. $14.84% was the measured parity or middle performance level for gross margin in ResMed Inc.'s peer group in 2023. $$4,223,000,000 was the measured advantage or top third performance level for gross revenue in ResMed Inc.'s peer group. $$3,922,000,000 was the measured parity or middle performance level for gross revenue in ResMed Inc.'s peer group in 2023. $$15,113,000,000 was the measured superior or top ten performance level for gross revenue in ResMed Inc.'s peer group in 2023.